Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 36Lung Neoplasms 7Brain Neoplasms 3Thyroid Neoplasms 2Neoplasms 2Gastrointestinal Neoplasms 2Breast Neoplasms 2Thyroid Cancer, Papillary 1Thoracic Neoplasms 1Sexual Dysfunction, Physiological 1Sarcoma 1Salivary Gland Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasms by Site 1Multiple Endocrine Neoplasia Type 2a 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Lung Diseases 1Intestinal Neoplasms 1Intestinal Diseases 1Head and Neck Neoplasms 1Genomic Instability 1Gastrointestinal Diseases 1Eunuchism 1Erectile Dysfunction 1Disease Resistance 1

Interventions

Crizotinib 2lorlatinib 1ceritinib 1brigatinib 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ALK-positive NSCLC × alectinib × Thoracic × Clear all
NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Pfizer

Completed
549 enrolled 28 charts
Thoracic

ALK-positive NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡